Edition:
United States

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

4.72USD
14 Dec 2018
Change (% chg)

$-0.38 (-7.45%)
Prev Close
$5.10
Open
$5.03
Day's High
$5.43
Day's Low
$4.61
Volume
55,611
Avg. Vol
54,552
52-wk High
$16.47
52-wk Low
$4.61

Latest Key Developments (Source: Significant Developments)

Selecta Biosciences Appoints Carsten Brunn, Ph.D. As President And CEO
Thursday, 27 Sep 2018 07:30am EDT 

Sept 27 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES APPOINTS CARSTEN BRUNN, PH.D. AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.SELECTA BIOSCIENCES INC - CARSTEN BRUNN, HAS BEEN APPOINTED CHIEF EXECUTIVE OFFICER OF SELECTA BIOSCIENCES, EFFECTIVE DECEMBER 1, 2018.SELECTA BIOSCIENCES INC - CARSTEN BRUNN WILL ALSO SERVE ON COMPANY'S BOARD OF DIRECTORS.SELECTA BIOSCIENCES - CURRENT CEO WERNER CAUTREELS WILL CONTINUE TO LEAD COMPANY UNTIL DECEMBER & WILL REMAIN MEMBER OF BOARD THROUGH DECEMBER 31.SELECTA BIOSCIENCES INC - CAUTREELS IS EXPECTED TO SERVE AS AN ADVISOR TO COMPANY FOLLOWING HIS RETIREMENT.  Full Article

Selecta Biosciences Announces Q2 Loss Per Share $0.84
Wednesday, 8 Aug 2018 08:00am EDT 

Aug 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.84.Q2 EARNINGS PER SHARE VIEW $-0.68 -- THOMSON REUTERS I/B/E/S.  Full Article

Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018
Monday, 8 Jan 2018 08:44am EST 

Jan 8 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING.SELECTA BIOSCIENCES - EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION FOR SEL-302 IN METHYLMALONIC ACIDEMIA IN 2019.  Full Article

Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy
Tuesday, 2 Jan 2018 08:05am EST 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY.SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018.  Full Article

Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End
Tuesday, 2 Jan 2018 08:00am EST 

Jan 2 (Reuters) - Selecta Biosciences Inc ::SELECTA BIOSCIENCES ANNOUNCES CEO’S INTENT TO RETIRE AND TRANSITION PLAN.SELECTA BIOSCIENCES INC - CEO WERNER CAUTREELS PLANS RETIREMENT AT END OF 2018.SELECTA BIOSCIENCES INC - OMID FAROKHZAD APPOINTED CHAIRMAN OF BOARD.SELECTA BIOSCIENCES INC - EXPECTS CAUTREELS TO REMAIN A MEMBER OF BOARD FOLLOWING HIS RETIREMENT.  Full Article

Selecta Biosciences announces Q3 loss per share $0.66
Tuesday, 7 Nov 2017 07:30am EST 

Nov 7 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces third quarter 2017 financial results and provides corporate update.Q3 revenue $100,000 versus $1.0 million.Q3 revenue view $383,000 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.66.Selecta -‍ Cash, cash equivalents, short-term deposits, investments & restricted cash sufficient to fund expenditure requirements into mid-2019​.  Full Article

Selecta Biosciences names John Leaman chief financial officer
Thursday, 26 Oct 2017 08:00am EDT 

Oct 26 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces important additions to senior leadership team.Selecta Biosciences Inc - ‍Appointment of John Leaman as company's new chief financial officer and head of corporate strategy​.  Full Article

Exclusive: KKR preps vending machine operator Selecta for $1 billion IPO - sources

FRANKFURT/LONDON Buyout group KKR has started preparations to list vending machine operator Selecta on the Swiss bourse as soon as the fourth quarter of 2018, people close to the matter said, adding to a flurry of major listings in the country.